Ninety days before starting ADHD medication, the risk of self-harm peaks—then begins to fall. That’s the finding from one of the largest global studies on ADHD treatment safety, offering reassurance to millions of families and patients who have long worried that the medication itself might increase the risk of self-harm.

For years, conflicting research has fueled hesitation. Some earlier studies raised concerns, making people afraid to start or stay on treatment, even as symptoms worsened. But now, a powerful new analysis led by Dr. Adrienne Chan and Professor Ian Wong at Aston University paints a clearer picture. Their team studied more than 460,000 people across five healthcare systems—Hong Kong, New Zealand, South Korea, Taiwan, and the U.K.—all of whom had started ADHD medication and had a history of self-harm between 2001 and 2020. By comparing risk levels in the 90 days before treatment, the first 90 days on medication, and beyond, they found a consistent pattern: the most dangerous time was right before treatment began.

The data showed that the risk of self-harm was highest in that pre-treatment window, not after. Once medication started, the risk dropped—though it remained elevated compared to the general population. This pattern held true across all five regions, suggesting it’s not a fluke of one healthcare system, but a meaningful signal. The study’s design, called a self-controlled case series, strengthens the findings by using each person as their own control, reducing the influence of other factors.

These results don’t just ease fears about medication—they point to a critical window for help. "Many people are already at their highest risk before treatment even begins," said Dr. Chan. That means the real issue may not be the drugs, but the delay in getting care. The study underscores the need to identify and support people earlier, especially when symptoms are worsening.

Beyond the immediate findings, the research has built something lasting: an international platform for studying medication safety. With partners from UCL, the University of Hong Kong, Seoul National University, Rutgers, and others, the team has shown how countries can collaborate using shared methods while keeping patient data secure. Future studies will explore what happens when people stop or restart medication, and whether social or ethnic disparities affect access to care.

This isn’t just about ADHD drugs. It’s about trust, timing, and turning data into care. As Professor Wong put it, the goal is to use big data not just to answer questions, but to help patients. For the millions living with ADHD, this study offers something powerful: clarity, and a chance to get help before crisis hits.